Does pharmaceutical GLP-1 cause thyroid cancer?
Posted: Tue Sep 15, 2026 9:29 pm
Because studies of drug safety in humans can vary dramatically in both the methodologies of data collection and data analysis—in addition to real-world biases, particularly financial conflicts of interest—two studies ostensibly asking the same question can draw dramatically different conclusions. This challenge is particularly apparent in the research surrounding pharmaceutical GLP-1 receptor agonists and thyroid cancer.
A landmark study in France, titled "GLP-1 Receptor Agonists and the Risk of Thyroid Cancer", published in Diabetes Care in 2023, examined 2,562 thyroid cancer cases (against 45,184 controls with type 2 diabetes) and found that those who used pharmaceutical GLP-1 for 1–3 years had an increased risk of all thyroid cancer and medullary thyroid cancer compared with matched patients without the same exposure. The study highlighted an association between pharmaceutical GLP-1 use and thyroid cancer, prompting calls for further investigation and clinical awareness regarding the drug's long-term safety profile.
By contrast, another landmark study in Scandinavia reached a different conclusion. Published in the British Medical Journal in 2024, the tri-nation cohort study evaluated 145,410 patients treated with pharmaceutical GLP-1 across Denmark, Norway, and Sweden, comparing them against 291,667 patients starting DPP-4 inhibitors. Over a mean follow-up period of nearly four years, the Scandinavian study found no statistically significant association between pharmaceutical GLP-1 use and thyroid cancer risk.
Which of these two studies is more accurate? It is important to understand that they were conducted differently, with each one taking a different look at the same problem. The French study found an association between pharmaceutical GLP-1 use and thyroid cancer, but an observational association does not establish causation. The Scandinavian study found no statistically significant association, but could not rule out the possibility of an association altogether.
What is indisputable, however, is that U.S. regulators consider the potential thyroid risk significant enough to warrant a specific contraindication for certain GLP-1 receptor agonists. Medications including semaglutide, dulaglutide, liraglutide, and exenatide are contraindicated in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. In the United States, the prescribing information for these medications also contains specific warnings about the potential risk of thyroid tumors. Whatever the ultimate conclusion of the ongoing research may be, the possibility of thyroid-related effects is not merely theoretical or something that exists only in academic debate; it is a risk that is explicitly recognized in the official safety information for these medications.
Last edited September 15, 2026.
A landmark study in France, titled "GLP-1 Receptor Agonists and the Risk of Thyroid Cancer", published in Diabetes Care in 2023, examined 2,562 thyroid cancer cases (against 45,184 controls with type 2 diabetes) and found that those who used pharmaceutical GLP-1 for 1–3 years had an increased risk of all thyroid cancer and medullary thyroid cancer compared with matched patients without the same exposure. The study highlighted an association between pharmaceutical GLP-1 use and thyroid cancer, prompting calls for further investigation and clinical awareness regarding the drug's long-term safety profile.
By contrast, another landmark study in Scandinavia reached a different conclusion. Published in the British Medical Journal in 2024, the tri-nation cohort study evaluated 145,410 patients treated with pharmaceutical GLP-1 across Denmark, Norway, and Sweden, comparing them against 291,667 patients starting DPP-4 inhibitors. Over a mean follow-up period of nearly four years, the Scandinavian study found no statistically significant association between pharmaceutical GLP-1 use and thyroid cancer risk.
Which of these two studies is more accurate? It is important to understand that they were conducted differently, with each one taking a different look at the same problem. The French study found an association between pharmaceutical GLP-1 use and thyroid cancer, but an observational association does not establish causation. The Scandinavian study found no statistically significant association, but could not rule out the possibility of an association altogether.
What is indisputable, however, is that U.S. regulators consider the potential thyroid risk significant enough to warrant a specific contraindication for certain GLP-1 receptor agonists. Medications including semaglutide, dulaglutide, liraglutide, and exenatide are contraindicated in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. In the United States, the prescribing information for these medications also contains specific warnings about the potential risk of thyroid tumors. Whatever the ultimate conclusion of the ongoing research may be, the possibility of thyroid-related effects is not merely theoretical or something that exists only in academic debate; it is a risk that is explicitly recognized in the official safety information for these medications.
Last edited September 15, 2026.